Schlech B A, Cagle G D
Curr Eye Res. 1981;1(7):409-17. doi: 10.3109/02713688109019979.
BB-K 122 is a new aminoglycoside antibiotic and an analogue of amikacin. This study evaluated the in vitro and in vivo activity of BB-K 122 and gentamicin against important ocular pathogens. BB-K 122 and gentamicin demonstrated generally equivalent in vitro antibacterial activity, except that gentamicin was more active against Streptococcus sp. BB-K 122 showed significant in vitro activity against important ophthalmic pathogens, including Pseudomonas aeruginosa, Staphylococcus aureus, Acinetobacter calcoaceticus, and species of Klebsiella, Escherichia, Proteus, Haemophilus, and Moraxella. Solutions of BB-K 122 (1%) and gentamicin sulfate (0.3%) were compared in an experimentally induced rabbit keratoconjunctivitis model. Rabbit eyes infected with P. aeruginosa or S. pneumoniae were treated with one of the two antibiotic formulations and evaluated after 24 h. A topical formulation of 1% BB-K 122 was at least as effective as gentamicin sulfate (0.3%) solution against these infections.
BB-K 122是一种新型氨基糖苷类抗生素,是阿米卡星的类似物。本研究评估了BB-K 122和庆大霉素对重要眼部病原体的体外和体内活性。BB-K 122和庆大霉素通常表现出相当的体外抗菌活性,不过庆大霉素对链球菌属的活性更强。BB-K 122对重要的眼科病原体具有显著的体外活性,这些病原体包括铜绿假单胞菌、金黄色葡萄球菌、醋酸钙不动杆菌以及克雷伯菌属、大肠杆菌属、变形杆菌属、嗜血杆菌属和莫拉菌属的菌种。在实验诱导的兔角膜结膜炎模型中,对BB-K 122溶液(1%)和硫酸庆大霉素溶液(0.3%)进行了比较。用这两种抗生素制剂之一治疗感染铜绿假单胞菌或肺炎链球菌的兔眼,并在24小时后进行评估。1% BB-K 122的局部制剂在对抗这些感染方面至少与硫酸庆大霉素(0.3%)溶液一样有效。